CTLA4 and neoplasm: Most immune checkpoints, including CTLA-4, PD-1, and PD-L1 with antibodies approved by the Food and Drug Administration (FDA), are expressed in exhausted T cells (Texh) that have encountered tumor antigens [14, 15].